Pan American League of Associations for Rheumatology recommendations for the management of Rheumatoid Arthritis, has been accepted for publication in The Lancet Rheumatology.

Producción CyT

Artículo

Autoría

Pedro Santos Moreno ; Garcia Salinas R ; CABALLERO VINICIO, CARLO ; BRANCE, MARIA LORENA ; MARIN ZUCARO, NM ; ARRIETA VEGA, DINA ; BELTRAN SONIA ; CABRERA SONIA ; CHACON DIAZ ROSA ; Corbacho, Inés ; FELIPE DIAZ OSCAR JAIR ; Gamboa R ; Gobby Carla ; GUERRERO GENEROSO BAUTISTA ; Adriana Maria Kakehasi ; LINHARES FERNANDA ; YIMMI MEDINA ; MONGE ZOLEDON PABLO ; RAMAGLI ALICIA ; STANGE LILITH ; STEKMAN YVAN ; VARGAS SARA ; FERREIRA GILDA ; FERNANDEZ AVILA DANIEL ; Brun LR ; ZAMORA NATALIA ; CARDIEL RIOS MARIO H ; CITERA GUSTAVO ; MYSLER EDUARDO ; TORO GUTIERREZ CARLOS E ; XAVIER RICARDO ; SORIANO ENRIQUE

Fecha

2025

Editorial y Lugar de Edición

ELSEVIER

Revista

LANCET RHEUMATOLOGY - ISSN 2665-9913
ELSEVIER

ISSN

2665-9913

Resumen Información suministrada por el agente en SIGEVA

The Pan American League of Associations for Rheumatology (PANLAR) developed evidence-based recommendations for the pharmacological management of rheumatoid arthritis (RA) in Latin America. A panel of RA experts formulated clinically relevant questions using the PICO format. Systematic literature reviews were conducted following the GRADE methodology, and recommendations were formulated based on evidence quality and expert consensus (≥70% agreement). The guideline includes ten recommendations... The Pan American League of Associations for Rheumatology (PANLAR) developed evidence-based recommendations for the pharmacological management of rheumatoid arthritis (RA) in Latin America. A panel of RA experts formulated clinically relevant questions using the PICO format. Systematic literature reviews were conducted following the GRADE methodology, and recommendations were formulated based on evidence quality and expert consensus (≥70% agreement). The guideline includes ten recommendations and a treatment algorithm. Key topics include early initiation of conventional disease- DMARDs —particularly methotrexate—parenteral MTX for intolerance, cautious glucocorticoid use, switching mechanisms of action after biologic/ targeted synthetic DMARDs failure, tapering in remission, and guidance for RA-associated ILD and vasculitis. Special attention is given to cost-effectiveness and accessibility in resource-constrained settings. These recommendations aim to support clinicians across the region by providing a practical, evidence-based, and contextually relevant framework that addresses the unique challenges faced in Latin America.

Ver más Ver menos

Palabras Clave

GUIDELINESRHEUMATOID ARTHRITISLATIN AMERICAN